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Abstract
Background: The aim of this study is to evaluate a new tumour marker, HE4, and to compare it with CA125 in
predicting optimal cytoreduction and response to chemotherapy. Thirty patients with advanced epithelial ovarian
cancer and multiple sera harvested during neoadjuvant chemotherapy (NAC) were included.
Results: Based on ROC curves analysis, CA125 ≤ 75 UI/ml and HE4 ≤ 252 pmol/L after the 3rd cycles of NAC, with
a sensitivity of 93.7 % and a specificity of 92.3 % (PPV = 93.7 % and NPV = 92.3 %), offered the best combination for
predicting optimal cytoreduction. In addition, the HE4 value of 115 pmol/L is the best cut-off level for identifying
platinum-sensitive patients.
Conclusions: The introduction of HE4 as a new tool for predicting platinum-sensitivity and interval optimal
cytoreduction is promising.
Keywords: CA125, HE4, Advanced ovarian cancer, Neoadjuvant chemotherapy, Optimal cytoreduction, Platinum
sensitivity, Predictive value
Background
Epithelial ovarian cancer remains the main cause of
mortality in patients with gynaecological malignancies.
The annual incidence of ovarian cancer is 204,000;
annualy, there are 125,000 deaths, and there is a close
correlation between the stage at presentation and
survival [1]. Cancer antigen 125 (CA125) is currently the
only serological biomarker in routine use for managing
patients with epithelial ovarian, fallopian tube and pri-
mary serous peritoneal cancer [2]. The upper limit of
normal for CA125 is 35 UI/ml. Several studies have
shown interest in using the CA125 value to predict
optimal debulking, to evaluate platinum sensitivity and
to monitor the disease after treatment [3].
Human epididymis protein 4 (HE4) is a novel and
specific biomarker of ovarian cancer, and its expression
is independent of CA125 [4]. The HE4 serum level in
healthy women has been reported to range from 60 to
150 pmol/L. This wide range may be due to the relation-
ship between increasing HE4 serum level and increasing
age [5, 6]. Serum HE4 is more specific than CA125 in
discriminating women with malignant tumors from
those with benign tumours [7].
In addition to its diagnostic value, the serum HE4 level
may be important for evaluating treatment response,
predicting optimal cytoreduction and monitoring
patients with ovarian cancer. Some teams have studied
the evolving profile of the HE4 level during neoadjuvant
chemotherapy (NAC) in small cohorts of patients
deemed currently inoperable [8–10]. Moreover optimal
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tumor debulking and platinum response are the most
important prognostic factors for overall survival in epi-
thelial ovarian cancer (EOC) [11].
In this study, we aimed to analyse the predictive role
of HE4 for surgical outcome and platinum response in
advanced stage EOC patients deemed inoperable and to
compare the results with those found for CA125.
Methods
Patients selection
Participants were recruited at two sites of Curie Institute
(Paris and Saint Cloud, France). From January 2002 and
December 2009, 117 patients with advanced epithelial
ovarian cancer (FIGO stage III and IV) received NAC.
Thirty patients had multiple sera collected during NAC
and available for study. The inclusion criteria were
the following: disease deemed inoperable and treated
by neoadjuvant platinum-based chemotherapy and in-
formed consent with agreement to undergo additional
testing for new markers or additional histological explo-
rations, even in hindsight. The protocol was reviewed
and accepted by the Institutional Review Board. The
patients underwent laparotomy or laparoscopy explor-
ation with minimal surgery (biopsies), which was followed
by NAC, interval debulking surgery and adjuvant chemo-
therapy. For each patient, the following clinical, biochem-
ical, radiological and pathological variables were collected:
age, weight, personal and family history, genetic predis-
position, disease characteristics (histology, stage, and
surgery) and relapse (treatment-free interval, location, and
management).
Measurement of CA125 and HE4
Venous blood samples were collected before chemo-
therapy treatment and interval debulking surgery. The
B-R-A-H-M-S CA125 II KryptorR technique (Hennigsdorf,
Germany), an automatic immunofluorescence analysis
kit for measuring CA125 in the serum or plasma, was
used to assay CA125. HE4 level was measured by a
fully automated chemiluminescent Enzyme Immunoassay
Lumipulse G HE4 (Fujirebio Europe, Gent, Belgium).
These measurements were performed retrospectively
from preserved samples. The threshold value for CA125
is commonly set < 35 UI/ml. The normal reference inter-
val for HE4 is 32–108 pmol/L (2.5th percentile, 97.5th
percentile) according the manufacturer.
Statistical analysis
Statistical analyses were performed with R Version
3.2.2 software. The data are presented as the mean +/−
standard derivation or median (range) and number (n).
The Wilcoxon-Mann–Whitney test was used to analyze
of quantitative variables, and the Fisher’s exact test was
used for qualitative variables. We calculated the accuracy,
sensitivity, specificity, positive and negative predictive
value (PPV and NPV) of CA125 and HE4 alone and com-
bined. Non-parametric receiver operating characteristic
(ROC) analyses was performed to determine the optimal
threshold of HE4 levels for predicting optimal surgery and
platinum-sensitivity. To calculate the misclassification
error rates we defined the best predictor using the Youden
point on the ROC curve. The Youden index (YI) is defined
as the maximum (sensitivity (YP) + specificity (YP) – 1),
that occurs at the optimum threshold, the Youden point
((YP) [12]. We used the Optimal Cutpoints package. The
diagnostic accuracy of the test was measured by the area
under the curve (AUC). The bootstrap method was used
to calculate 95 % confidence intervals. For the optimal
threshold of the CA125 levels, we checked and used pre-
viously published thresholds. The overall survival was
estimated using the Kaplan-Meier method and compared
using the log-rank test. The platinum-free interval (PFI) is
defined as the interval from the end of platinum-based
chemotherapy to first recurrence. We chose the threshold
value of 6 months to evaluate whether the disease was
sensitive to platinum. The diagnosis of recurrence was
based on clinical symptoms, clinically detectable disease
and/or radiological evidence of disease recurrence. To
assess the prognosis and peritoneal surface malignancy,
we used the completeness of cytoreduction (CC) score,
where CC-0 is defined as no residual macroscopic lesion
after cytoreduction and CC-1, 2 and 3 (CC-1+) scores
(tumour nodules persisting after cytoreduction less than
2.5 mm, between 2.5 mm and 2.5 cm, and greater than
2.5 cm or a confluence of unresected tumor nodules,
respectively) were grouped together [13]. For all statistical
comparisons, a p-value of < 0.05 was considered statisti-
cally significant.
Results
The clinical characteristics and laboratory variables of
the studied groups are reported in Table 1. The search
for a genetic predisposition is made in accordance with
age of patient, personal and family medical history. An
oncogenetic consultation has been proposed for eight
patients (less than one-third of our cohort). One mutated
patient was found (BRCA1 mutation). Complete interval
debulking surgery (IDS) was achieved in 16 of 30 (53 %)
patients and was not complete in 14 of 30 (47 %) patients.
The median age was 62.8 years (range 40–79). Ninety
percent of patients were menopausal. All patients had
serous adenocarcinoma and 50 % had grade 3 tumours
according to final histology. All patients were eligible for
NAC and had received taxane and platinum-based NAC.
Building on our previous publications, we studied the
tumour markers rates after the 3rd cycle of NAC [B].
The mean pre-NAC HE4 level was 928 pmol/L (range
46–6562 pmol/L) in the CC-0 group and 984 pmol/L
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(range 153–2746 pmol/L) in the CC-1+ group, and there
was no significant difference. The mean pre-NAC CA125
level was 1432 UI/ml (range 16–9453 UI/ml) in the CC-0
group and 2257 UI/ml (range 632–9400 UI/ml) in the
other. In our population, based on the ROC curve, the
CA125 value of 75 UI/ml is the best cut-off to identify the
patient candidates that are optimal cytoreduction agents
with a sensitivity of 81.3 % and a specificity of 85.7 %
(PPV = 86.7 % and NPV= 80 %). For CA125, the AUC is
0.92 (95 % confidence interval (CI) [0.80–1]). Instead, the
cut-off level of HE4 with the best prognostic indices is 252
pmol/L, with a sensitivity of 93.3 %, a specificity of 50 %
(PPV = 70 % and NPV = 85.7 %), and an AUC of 0.86
(95 % CI [0.68–1]). The CA125 and HE4 AUC indicate
there is a good discrimination capability between the
optimal and not optimal IDS cases. The cut-off for the
combination of CA125 and HE4 considered in our study
has a sensitivity of 93.7 % and a specificity of 92.3 % (PPV
= 93.7 % and a NPV = 92.3 %). These results were signi-
ficant and are summarized in Tables 2 and 3. In terms of
survival, a trend towards improvement in overall survival
was observed (Fig. 1) in the case of CA125, with HE4
decreasing below the thresholds above-mentioned.
In our cohort, 12 patients (40 %) experienced recur-
rence in the first 6 months, and 18 patients (60 %) were
considered platinum-resistant with a first relapse after
6 months. The clinical and biological characteristics
were similar in both groups (Table 1). The average value
of pre-NAC HE4 and CA125 were similar in both groups
and were statistically not significant. In 30 women with
EOC, HE4 appear to improve the prediction of the plat-
inum sensitivity (Table 2). Based on ROC analysis, the
CA125 and HE4 cut-off values for predicting platinum
sensitivity were 35 UI/ml and 115 pmol/L, respectively,
and they were accompanied by AUC values of f 0.80
(95 % CI [0.62–0.94]) and 0.88 (95 % CI [0.73–0.98]),
respectively, for CA125 and HE4. At the ideal cut-off,
corresponding to the highest accuracy (minimal false-
Table 1 Patient characteristics
Characteristics Overall population
(n = 20)
CC-0 (n = 16) CC-1+ (n = 14) p-value Relapse < 6 months
(n = 12)
Relapse > 6 months
(n = 18)
p-value
Age (years) 62.8 +/− 10.77 63.62 +/− 8.62 61.93 +/− 13.09 0.92 63.57 +/− 11.95 62.2 +/− 9.97 0.63
BMI (kg/m2) 23.64 +/− 3.39 23.69 +/− 2.91 23.59 +/− 3.98 0.77 22.75 +/− 3.04 24.42 +/− 3.58 0.24
Gestity 1.81 +/− 1.49 1.94 +/− 1.95 1.64 +/− 1.69 0.45 1.23 +/− 1.47 1.80 +/− 1.57 0.90
Parity 1.74 +/− 1.65 1.75 +/− 1.24 1.73 +/− 2.20 0.51 1.92 +/− 1.98 1.60 +/− 1.40 0.86
Menopause 27 (90 %) 15 (93.7 %) 12 (85.7 %) 0.59 10 (83.3 %) 17 (94.4 %) 0.59
FIGO stage 1 0.63
IIIa 1 (3.31 %) 1 (6.25 %) 0 0 1 (5.55 %)
IIIb 1 (3.31 %) 1 (6.25 %) 0 0 1 (5.55 %)
IIIc 23 (76.7 %) 12 (75 %) 11 (78.6 %) 9 (75 %) 14 (77.8 %)
IV 5 (16.67 %) 2 (12.5 %) 3 (21.4 %) 3 (25 %) 2 (11.1 %)
Grading 0.26 0.63
I 3 (10 %) 3 (18.7 %) 0 0 3 (16.7 %)
II 9 (30 %) 5 (31.3 %) 4 (35.7 %) 5 (41.7 %) 4 (22.2 %)
III 15 (50 %) 6 (37.5 %) 9 (64.3 %) 5 (41.7 %) 10 (55.6 %)
Pre-NAC CA-125 (UI/ml) 1762.63 [16–9453] 1432.89 [16–9453] 2257.25 [302–9400] 0.05 1884.07 [16–9453] 1656.8 [57–9400] 0.15
Pre-NAC HE4 (pmol/l) 985.3 [46.1–6562] 928.22 [46.1–6562] 984.26 [153.2–2746] 0.24 1374.59 [63.9–6562] 644.66 [46.1–2031] 0.13
Cycles of NAC 5.75 [3–7] 5.5 [3–6] 6.12 [6–7] 0.08 5.60 [3–7] 5.62 [4–6] 0.69
CC-0 non residual disease after interval debulking surgery (IDS), CC-1+ residual disease after IDS
BMI body mass index, FIGO International Federation of Gynecology and Obstetrics, NAC neoadjuvant chemotherapy
Table 2 Tumour markers after the 3rd cycle of NAC and the
interval surgery outcome (a) or first relapse (b)
(a)
CC-0 (n = 16) CC-1+ (n = 14) p-value
CA125≤ 75 UI/ml 13 (81.3 %) 2 (12.3 %) 0.0007
HE4≤ 252 pmol/l 14 (87.5 %) 6 (42.8 %) 0.02
CA125≤ 75 UI/ml and
HE4≤ 252 pmol/l









CA125≤ 35 UI/ml 1 (8.3 %) 10 (55.5 %) 0.018
HE4≤ 115 pmol/l 1 (8.3 %) 13 (72.2 %) 0.0017
CA125≤ 35 UI/ml and
HE4≤ 115 pmol/l
1 (8.3 %) 13 (72.2 %) 0.0017
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negative and false-positive results), HE4 and the combi-
nation CA125 +HE4 resulted in a similar sensitivity,
specificity, PPV and NPV (Table 3).
Discussion
Ovarian cancer is usually diagnosed at an advanced
stage. In the advanced stage, many patients have multiple
peritoneal locations, making it difficult to completely
debulk the tumours in these patients. Based on numerous
recent studies, NAC appears to be a valuable option
for patients who cannot undergo surgery with optimal
cytoreduction performed on them [14, 15]. An optimal
surgical outcome is one of the most powerful deter-
minants of survival [13]. NAC, followed by surgical
debulking, can achieve survival rates that are equivalent
to that observed with primary surgical debulking followed
by adjuvant chemotherapy [14]. First-line of chemothe-
rapy is based on platinum in ovarian cancer. The pla-
tinum response is an independent prognostic factor for
the overall and progression-free survival in patients with
EOC [16]. Unfortunately, there has been no general
consensus on the best preoperative approach to predict
cytoreductibility. Similarly, it is difficult to predict the
platinum sensitivity of the disease before the first relapse.
Several studies have evaluated the role of CA125 in pre-
dicting cytoreductibility. For patients receiving primary
cytoreduction, a preoperative CA125 level of 500 UI/ml
was used as the proper cut-off limit for this purpose
[17–22]. For patients receiving NAC, different cut-offs
were published, ranging from 20 to 100 UI/ml [23–25].
Our result indicates that a CA125 level after the 3rd cycle
of NAC of 75 UI/ml could help identify patients in whom
optimal cytoreduction will be achieved. The same cut-off
was published by Braicu et al. [26]. HE4 is a new tumour
marker that was recently approved for diagnosing and
monitoring ovarian cancer [5]. Data on the role of HE4 in
the carcinogenesis are inconsistent. There are a few small
studies evaluating the profile of HE4 during NAC in a
primarily inoperable ovarian cancer patient cohort [8–10].
A study of 10 patients showed that the profile of HE4
during NAC was in line with radiologic and clinical re-
sponses. In the NAC group, HE4 correlated better with
the radiologic response than CA125 [10]. A Yang et al.
showed that 600 pmol/L is the cut-off value for HE4,
above that level cytoreductive surgery should be deferred
and the sensitivity and specificity of the test were 77 and
32 %, respectively [27]. In our study, the cut-off value
for HE4 was lower; calculated based on the method by
Youden,it was 255 pmol/L resulting in a sensitivity and
specificity of 91.7 and 67 %, respectively. Angioli et al.
(262 pmol/L), Chudecha-Glaz et al. (218.43 poml/L) and
Braicu et al. (250 pmol/L) presented HE4 cut-off values
that were similar to ours [26, 28, 29]. At the same time,
they showed that HE4 is a better predictor than CA125
of the feasibility of optimal cytoreduction. In our study,
HE4 and CA125 show similar performance in predicting
surgical cytoreduction with diagnostic odds ratios (DOR)
Table 3 Performance tumour markers in predicting
cytoreduction (a) or platinum sensitivity (b)
Sensitivity Specificity PPV NPV DOR
(a)
CA125≤ 75 UI/ml 81.3 % 85.7 % 86.7 % 80 % 22.13
HE4≤ 252 pmol/l 93.3 % 50 % 70 % 85.7 % 12.57
CA125≤ 75 UI/ml and
HE4≤ 252 pmol/l
93.7 % 92.3 % 93.7 % 92.3 % 96.15
(b)
CA125≤ 35 UI/ml 90.9 % 57.9 % 55.6 % 91.7 % 13.75
HE4≤ 115 pmol/l 92.9 % 68.7 % 72.2 % 91.7 % 28.6
CA125≤ 35 UI/ml and
HE4≤ 115 pmol/l
92.9 % 68.7 % 72.2 % 91.7 % 28.6
PPV positive predictive value, NPV negative predictive value, DOR diagnostic
odd ratio
p=0.60 p=0.54p=0.97
Fig. 1 Kaplan-Meier estimates of the overall survival according to CA125 and HE4 cut-offs for predicting the optimal interval debulking surgery
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of 21.97 and 21.00 respectively. In combination, the diag-
nostic accuracy is strongly enhanced with a DOR above
500 (Table 3). The best factor in predicting cytoreduction
was the combination of CA125 ≤ 75 UI/ml and HE4 ≤ 252
pmol/L, which had a sensitivity of 93.7 % and specificity of
92.3 % (PPV = 93.7 % and NPV = 92.3 %). Angioli et al.
showed similar results with a sensitivity of 88.8 % and
specificity of 89.5 % (PPV = 94 % and NPV= 80 %) for the
combination CA125 (≤414 UI/ml) + HE4 (≤262 poml/L).
However, in this publication, the best association in pre-
dicting primary cytoreduction is HE4 level ≤ 262 pmol/L
and ascites ≤ 500 ml (sensitivity = 100 %, specificity =
89.5 %, and n = 36 patients). To the best of our knowledge,
no publication is available on the ability of HE4 to predict
platinum sensitivity. Unfortunately, it is difficult to com-
pare our data. The benefit of HE4 for predicting platinum
sensitivity seems limited. Larger population studies are
needed to evaluate these data.
The limitations of our study include its retrospective
nature and probable selection bias. In addition, the HE4
levels were not available for some patients, limiting the
number of patients whose data could be analyzed and
the statistical power of our analysis. This is a pilot study
and larger studies are needed.
Conclusions
In conclusion, CA125 is still the only tumour marker
that is recommended as a diagnostic or prognostic indica-
tor and for monitoring disease recurrence after surgery
and chemotherapy [30]. HE4 had comparable diagnostic
performance with CA125 as a tumour marker for detec-
ting ovarian cancer. HE4 was more sensitive and specific
in detecting the early stages of ovarian cancer and more
specific [30]. Based on our results and the literature, the
introduction of HE4, alone or combined with CA125, as a
new tool for predicting platinum-sensitivity and primary
or interval optimal cytoreduction is promising.
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